Finerenone Dosing Regimen
For patients with type 2 diabetes and chronic kidney disease with albuminuria, initiate finerenone at 10 mg daily if eGFR is 25-60 mL/min/1.73 m², or 20 mg daily if eGFR is >60 mL/min/1.73 m², provided serum potassium is ≤4.8 mmol/L (or ≤5.0 mmol/L per FDA label). 1
Initiation Criteria
Before starting finerenone, verify the patient meets these requirements:
- Type 2 diabetes with CKD and persistent albuminuria (ACR ≥30 mg/g) despite maximum tolerated RAS inhibitor therapy 2, 1
- eGFR ≥25 mL/min/1.73 m² at baseline 2
- Serum potassium ≤4.8 mmol/L (trial criteria) or ≤5.0 mmol/L (FDA label) 2
- Patient should already be on standard-of-care treatment including glucose-lowering and antihypertensive medications 2
Dose Selection Algorithm
Starting dose is determined solely by baseline eGFR:
- eGFR >60 mL/min/1.73 m²: Start 20 mg once daily 2, 1
- eGFR 25-60 mL/min/1.73 m²: Start 10 mg once daily 2, 1
The 2024 KDIGO guidelines provide clear dosing tables that align with this eGFR-based approach 1. Real-world data from FINE-REAL confirms that 81% of patients appropriately initiated at 10 mg based on their kidney function 3.
Titration Protocol
Monitor potassium at 1 month after initiation, then every 4 months 1
Uptitration decision based on potassium level:
- K+ ≤4.8 mmol/L: Uptitrate from 10 mg to 20 mg daily 2, 1
- K+ 4.9-5.5 mmol/L: Continue current dose (10 mg or 20 mg); monitor K+ every 4 months 1
- K+ >5.5 mmol/L: Hold finerenone immediately 2, 1
For patients started on 10 mg: If potassium remains ≤4.8 mmol/L at the 1-month check, uptitrate to 20 mg daily. In the FINE-REAL study, 26% of patients starting at 10 mg successfully uptitrated to 20 mg during follow-up 3.
Management of Hyperkalemia
If potassium rises above 5.5 mmol/L:
- Immediately discontinue finerenone 2, 1
- Adjust diet and review concomitant medications that may contribute to hyperkalemia 1
- Recheck potassium levels regularly
- Restart at 10 mg daily when potassium returns to ≤5.0 mmol/L 2, 1
This approach is critical because hyperkalemia occurred in only 5-8% of patients in real-world studies when proper monitoring was implemented, with no cases leading to death, dialysis, or hospitalization 3, 4.
Continuation with Declining Kidney Function
Finerenone can be continued even if eGFR falls below 25 mL/min/1.73 m² during treatment, as long as potassium remains acceptable and the drug is tolerated 2. This is an important distinction—the eGFR threshold of ≥25 mL/min/1.73 m² applies to initiation only, not continuation.
Contraindications
Absolute contraindications:
- Baseline potassium >5.0 mmol/L (FDA) or >4.8 mmol/L (trial criteria) 2
- eGFR <25 mL/min/1.73 m² at initiation 2, 1
- Concomitant use with strong CYP3A4 inhibitors (drug interaction concern) 5
Relative contraindications requiring caution:
- History of recurrent hyperkalemia
- Concurrent use of other potassium-sparing agents beyond RAS inhibitors
- Patients unable to comply with regular potassium monitoring
Clinical Context
The 2024 KDIGO guidelines (the most recent and authoritative source) recommend nonsteroidal MRAs like finerenone for adults with T2D who remain at high risk despite standard therapies 1. The 2022 ADA/KDIGO consensus report established that finerenone should be added to treatment regimens for patients with any level of persistent albuminuria despite current standard of care 2.
Key advantage over steroidal MRAs: Finerenone demonstrates reduced hyperkalemia risk compared to traditional agents like spironolactone, making it safer for patients with moderate-to-severe CKD 5. Real-world data shows 85% of patients remain on continuous therapy for up to 1 year, with only 1% discontinuing due to hyperkalemia 3.
Combination therapy: Finerenone may be safely added to RAS inhibitors and SGLT2 inhibitors, providing complementary cardiorenal protection 1. This layered approach addresses multiple pathophysiologic mechanisms in diabetic kidney disease.